Cargando…
Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension
OBJECTIVE: To assess the efficacy and safety of subcutaneous treprostinil in adult patients with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH) after 12 months of treatment. METHODS: Consecutive adult patients with CHD–PAH received subcutaneous treprostinil to maximu...
Autores principales: | Skoro-Sajer, Nika, Gerges, Christian, Balint, Olga Hajnalka, Kohalmi, Dora, Kaldararova, Monika, Simkova, Iveta, Jakowitsch, Johannes, Gabriel, Harald, Baumgartner, Helmut, Gerges, Mario, Sadushi-Kolici, Roela, Celermajer, David S, Lang, Irene Marthe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6047165/ https://www.ncbi.nlm.nih.gov/pubmed/29436381 http://dx.doi.org/10.1136/heartjnl-2017-312143 |
Ejemplares similares
-
Surgical specimens, haemodynamics and long-term outcomes after pulmonary endarterectomy
por: Skoro-Sajer, Nika, et al.
Publicado: (2014) -
The risk profile change in patients with severe chronic thromboembolic pulmonary hypertension treated with subcutaneous treprostinil
por: Jansa, Pavel, et al.
Publicado: (2023) -
Treprostinil for pulmonary hypertension
por: Skoro-Sajer, Nika, et al.
Publicado: (2008) -
Local and Systemic RAGE Axis Changes in Pulmonary Hypertension: CTEPH and iPAH
por: Moser, Bernhard, et al.
Publicado: (2014) -
Bicuspid aortic valve: different clinical profiles for subjects with versus without repaired aortic coarctation
por: Lim, Michelle S, et al.
Publicado: (2020)